Gene Therapy Trials And Regulatory Approvals Will Open New Frontiers

Published
02 Apr 25
Updated
20 May 25
AnalystConsensusTarget's Fair Value
US$6.48
84.4% undervalued intrinsic discount
20 May
US$1.01
Loading
1Y
-22.3%
7D
-3.8%

Author's Valuation

US$6.5

84.4% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on24 Apr 25
Fair value Decreased 14%

AnalystConsensusTarget has increased revenue growth from 198.4% to 228.1%, decreased profit margin from 17.3% to 15.6%, decreased future PE multiple from 156.7x to 95.5x and decreased shares outstanding growth rate from 0.1% to 0.0%.

Shared on17 Apr 25

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 140.4x to 156.7x.

Shared on09 Apr 25
Fair value Increased 11%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.